RADNOR, Pa., June 15, 2021 /PRNewswire/ — NRx Pharmaceuticals (Nasdaq: NRXP), a clinical stage pharmaceutical company, today announced positive data from its ZYESAMITM (Aviptadil) Expanded Access ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback